Novartis will seek regulatory approval this year for a new kind of anti-inflammatory heart drug, though some experts fear fatal infection risks and a high price may overshadow the medicine's limited benefits. More »
FILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland, January 25, 2017. REUTERS/Arnd Wiegmann/File Photo Novartis AG on Wednesday said the U.S. Food and Drug Administration (FDA) has agreed to accelerate its rev... More »
The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel, Switzerland October 22, 2013. REUTERS/Arnd Wiegmann/File Photo Swiss drugmaker Novartis’s bid to bolster its eye drug portfolio suffered a setback on Monday when it announced combining ... More »
The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel, Switzerland October 22, 2013. REUTERS/Arnd Wiegmann/File Photo Novartis’s psoriasis drug Cosentyx showed long-term efficacy in keeping patients’ skin clear, the Swiss drugmaker said on ... More »
A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013. REUTERS/Vivek Prakash/File Photo Novartis’s investigational multiple sclerosis drug cut the risk of disability progression in patients with a tough-to-treat form of the disease v... More »
